Crosslaps - Serum Deoxypyridinoline (DPD)
Private Crosslaps - Serum Deoxypyridinoline (DPD) blood test in London for £164, assessing one bone resorption marker with results in around 5 days.
Turnaround time
5 business days
Biomarkers count
1
Book your test
Choose Service Type
Professional phlebotomist comes to you
+ £{{ home_visit_fee }}
Visit our clinic for your test
{{ clinic_visit_fee > 0 ? '+ £' + clinic_visit_fee : 'Free' }}
Home Visit Details
Home visits require at least 24 hours notice.
Select a clinic: Sorting by distance…
{{ clinicAddress(clinic) }}
{{ clinicAddress(selectedClinic) }}
Select a date
Select an hour
Available time slots: {{ timeSlots.length}}
Overview of the Crosslaps - Serum Deoxypyridinoline (DPD)
The Crosslaps - Serum Deoxypyridinoline (DPD) test is a specialist blood investigation used to assess biochemical activity associated with bone resorption.
The test contains 1 biomarker: Crosslaps (Serum DPD).
Bone is continuously remodelled throughout life.
Older bone is broken down by osteoclasts while new bone is produced by osteoblasts.
DPD refers to deoxypyridinoline, a collagen cross-link associated with breakdown of mature type I collagen, which is abundant in bone.
Bone-resorption markers therefore provide information about current skeletal turnover.
This is fundamentally different from a DEXA scan.
DEXA measures bone mineral density, whereas biochemical turnover markers provide information about current bone-remodelling activity.
The test may be useful when monitoring treatment for osteoporosis, because biochemical changes in bone resorption can occur before measurable changes in bone density.
A high result does not independently diagnose osteoporosis.
Likewise, a normal result does not guarantee normal bone density or low fracture risk.
Results should be interpreted alongside age, sex, menopausal status, medication, kidney function, vitamin D, calcium and DEXA findings where available.
What Does the Crosslaps - Serum Deoxypyridinoline (DPD) Test Check?
This test measures 1 biomarker.
Crosslaps (Serum DPD)
Measures a biochemical marker associated with collagen breakdown and bone resorption, providing information about current skeletal turnover.
Who May Benefit From the Crosslaps - Serum Deoxypyridinoline (DPD) Test?
This specialist test may be useful where current bone-resorption activity needs to be assessed or monitored.
People with osteoporosis undergoing treatment monitoring - Bone-turnover markers can change before measurable improvements in bone density occur.
People with osteopenia undergoing a wider bone-health assessment - The test may complement DEXA and clinical fracture-risk assessment.
Postmenopausal women at increased risk of bone loss - Bone resorption commonly accelerates after menopause.
People taking long-term corticosteroids - Corticosteroids can adversely affect bone metabolism and fracture risk.
People with metabolic bone disease - Bone-turnover markers may complement calcium, phosphate, Vitamin D and endocrine testing.
People receiving anti-resorptive osteoporosis medication - Serial testing may show whether treatment is suppressing bone breakdown.
People with a previous abnormal bone-turnover marker - Repeat measurement can help assess trends.
People specifically advised to obtain Crosslaps (Serum DPD) - Specialist interpretation is particularly useful for this marker.
How to Prepare
Do not stop osteoporosis treatment simply to alter a bone-turnover result.
Serial measurements are most useful when preparation, timing and laboratory methodology remain consistent.
Symptoms and Reasons to Consider the Crosslaps - Serum Deoxypyridinoline (DPD) Test
Bone loss frequently develops without symptoms. Crosslaps testing is therefore usually considered because of risk factors, treatment monitoring or previous bone findings rather than a specific symptom.
A diagnosis of osteoporosis - Bone-resorption testing may provide supplementary information during treatment monitoring.
A diagnosis of osteopenia - Increased bone turnover may provide additional context when combined with DEXA findings.
A previous low-trauma or fragility fracture - Fracture history can indicate increased skeletal fragility and warrants broader bone-health assessment.
Loss of height over time - Progressive height loss can occur with vertebral compression fractures.
Persistent back pain with osteoporosis risk factors - Vertebral fractures can sometimes present with back pain.
Long-term corticosteroid treatment - Steroids increase fracture risk and can alter bone metabolism.
Early menopause or prolonged oestrogen deficiency - Reduced oestrogen can accelerate bone resorption.
Previous abnormal bone-turnover results - Repeat testing can assess whether bone-resorption activity has changed.
Monitoring after starting osteoporosis medication - Biochemical markers may respond earlier than bone-density measurements.
Osteoporosis often causes no symptoms until a fracture occurs.
Crosslaps does not diagnose osteoporosis and should not replace DEXA scanning or formal fracture-risk assessment. Sudden severe back pain, loss of mobility or suspected fracture requires appropriate clinical assessment.
How to Book Your Crosslaps - Serum Deoxypyridinoline (DPD) Test
Because this is a specialist bone-turnover assay, an appropriate sample-collection pathway should be used.
Choose the Crosslaps - Serum Deoxypyridinoline (DPD)
Select the individual bone-resorption test.
Select your sample collection option
Arrange a clinic or professional collection route capable of meeting the laboratory processing requirements.
Attend your appointment
A trained healthcare professional collects the required venous blood sample.
Laboratory analysis
Your specimen is processed and analysed for Crosslaps (Serum DPD).
Receive your results securely
Your authorised bone-turnover result is delivered securely.
When Will I Receive My Results?
The current expected turnaround time is approximately 5 days after the sample reaches the laboratory.
Specialist sample processing or repeat analysis may occasionally extend reporting.
Understanding Your Results
A lower bone-resorption marker generally indicates less measurable collagen breakdown at the time of testing.
In someone receiving effective anti-resorptive treatment, a fall from baseline may be consistent with a biochemical treatment response.
A higher result suggests increased bone-resorption activity.
Possible influences include menopause, metabolic bone disease, untreated osteoporosis and other conditions associated with altered skeletal turnover.
The result is not a direct measurement of bone density.
A high result does not diagnose osteoporosis, and a normal result does not rule it out.
Reference intervals can vary according to age, sex and menopausal status.
For monitoring, the change from an individual's previous result can be particularly useful.
Why Book With London Blood Tests?
Private bone-turnover testing in London - Access specialist Crosslaps (Serum DPD) measurement privately.
Measures current bone-resorption activity - The test provides biochemical information that differs from bone-density imaging.
Useful during osteoporosis treatment monitoring - Serial measurements can help assess biochemical response to anti-resorptive treatment.
Relevant to metabolic bone assessment - The marker can complement Vitamin D, calcium and endocrine investigations.
Specialist laboratory analysis - Your sample undergoes dedicated bone-turnover testing.
Professional sample handling - Appropriate collection and processing can be arranged.
Secure reporting - Receive your authorised result securely.
Clear pricing - Crosslaps - Serum Deoxypyridinoline (DPD) costs £164.
Private Crosslaps - Serum Deoxypyridinoline (DPD) Blood Test in London
London Blood Tests provides private Crosslaps - Serum Deoxypyridinoline (DPD) testing in London for people requiring specialist assessment of bone-resorption activity.
The test costs £164 and measures one biomarker: Crosslaps (Serum DPD).
It may be useful during osteoporosis treatment monitoring and wider metabolic bone assessment.
Results are expected approximately 5 days after laboratory receipt.